Dr. William on Brentuximab Vedotin/Lenalidomide in Cutaneous/Peripheral T-Cell Lymphomas
1 Tampilan
• 08/09/23
0
0
Menanamkan
administrator
Pelanggan
Basem William, MD, MRCP, FACP associate professor of internal medicine, The Ohio State University, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive/
Menampilkan lebih banyak
Komentar Facebook
SORT BY-
Komentar Teratas
-
komentar terbaru